Abacavir/lamivudine/zidovudine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Abacavir/lamivudine/zidovudine
Combination of
Abacavir Nucleotide analogue reverse transcriptase inhibitor
Lamivudine Nucleoside analogue reverse transcriptase inhibitor
Zidovudine Nucleoside analogue reverse transcriptase inhibitor
Clinical data
Trade names Trizivir
AHFS/Drugs.com FDA Professional Drug Information
MedlinePlus a687007
Pregnancy cat.
Legal status
Routes Oral
Identifiers
CAS number  YesY
ATC code J05AR04
ChemSpider 21106400 YesY
NIAID ChemDB 058986
 YesY (what is this?)  (verify)

Abacavir/lamivudine/zidovudine (INNs, trade name Trizivir) is a pharmaceutical treatment for HIV infection. It is a fixed dose combination of three reverse transcriptase inhibitors patented by GlaxoSmithKline and now marketed by its joint venture with Pfizer, ViiV Healthcare:[1]

It is indicated in the treatment of AIDS/HIV.[2] For this purpose, the combination is very useful in pregnant women to decrease the risk of mother-to-child transmission.[3]

The combination of drugs helps to reduce HIV's resistance (through mutation) to the drugs individually. Of the three, AZT and ABC have passed out of United States patent protection.

In December 2013, Lupin Limited launched a generic version of Trizivir. [4] [5]

References[edit]

  1. ^ InPharm.com: GlaxoSmithKline-Pfizer launch HIV joint venture
  2. ^ Drugs.com: Trizivir
  3. ^ Horvath, Tara; Madi, Banyana C; Iuppa, Irene M; Kennedy, Gail E; Rutherford, George W; Read, Jennifer S.; Horvath, Tara (2009). Interventions for preventing late postnatal mother-to-child transmission of HIV. doi:10.1002/14651858.CD006734.pub2. 
  4. ^ Monthly Prescribing Reference (MPR): [1]
  5. ^ Lupin Pharma: [2]